GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TFF Pharmaceuticals Inc (NAS:TFFP) » Definitions » Equity-to-Asset

TFF Pharmaceuticals (TFF Pharmaceuticals) Equity-to-Asset : 0.80 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is TFF Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. TFF Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $9.57 Mil. TFF Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $12.03 Mil.

The historical rank and industry rank for TFF Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

TFFP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.8   Med: 0.95   Max: 0.97
Current: 0.8

During the past 7 years, the highest Equity to Asset Ratio of TFF Pharmaceuticals was 0.97. The lowest was 0.80. And the median was 0.95.

TFFP's Equity-to-Asset is ranked better than
67.99% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs TFFP: 0.80

TFF Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for TFF Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TFF Pharmaceuticals Equity-to-Asset Chart

TFF Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.95 0.97 0.95 0.95 0.80

TFF Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.91 0.91 0.92 0.80

Competitive Comparison of TFF Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, TFF Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TFF Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TFF Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where TFF Pharmaceuticals's Equity-to-Asset falls into.



TFF Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

TFF Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=9.567/12.027
=

TFF Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=9.567/12.027
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TFF Pharmaceuticals  (NAS:TFFP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


TFF Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of TFF Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


TFF Pharmaceuticals (TFF Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.
Executives
Carlson Capital L P 10 percent owner 2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201
Clint Duane Carlson 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Zamaneh Mikhak officer: Chief Medical Officer 1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107
Robert S Mills director 8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812
Kirk Allen Coleman officer: CFO, Secretary, and Treasurer 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Asgard Investment Corp. Ii 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Double Black Diamond Offshore Ltd 10 percent owner CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Brandi Roberts director 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Glenn R. Mattes director, officer: President and CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Malcolm Fairbairn director C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563
Lung Therapeutics, Inc. 10 percent owner P.O. BOX 150183, AUSTIN TX 78715

TFF Pharmaceuticals (TFF Pharmaceuticals) Headlines

From GuruFocus

TFF Pharmaceuticals Announces Leadership Transition

By Value_Insider Value_Insider 12-05-2022